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Abstract
Background: The presence of a Type III secretion system in clinical isolates of Pseudomonas
aeruginosa  is associated with severe disease and poor outcomes in infections caused by this
pathogen. We describe an indirect enzyme-linked immunosorbent assay that rapidly and
quantitatively detects two exotoxins, ExoU and ExoT, and two structural components, PopD and
PcrV, of the P. aeruginosa Type III secretion system after in-vitro growth in a calcium-free minimal
medium.
Methods: We used this assay to characterize the Type III secretion phenotype of 74 clinical
isolates of P. aeruginosa. Findings were compared with results of standard immunoblotting and
correlated with Type III secretion-dependent virulence of isolates toward cultured epithelial cells.
Results: Results of the ELISA assay were concordant with immunoblot detection of the secreted
antigens for 73 of 74 isolates. The Type III secretion phenotype assessed by this immunoassay
predicted bacterial virulence toward epithelial cells in vitro for all but five of the clinical isolates.
Conclusion: The availability of an ELISA assay for rapid detection of Type III secreted virulence
factors will facilitate large clinical studies to examine whether the Type III secretion phenotype of
a P. aeruginosa isolate predicts the course of clinical disease in a patient and should be taken into
account in determining optimal treatment strategies for infected patients.
Background
Pseudomonas aeruginosa is a gram-negative human patho-
gen that causes acute infections associated with significant
morbidity and mortality, particularly among hospitalized
patients and immunocompromised individuals [1]. Many
P. aeruginosa isolates express a specialized protein secre-
tion system, called the Type III secretion system (T3SS)
[2,3]. Three studies have demonstrated that more severe
manifestations of P. aeruginosa acute infection, such as
bacteremia, relapsing pneumonia, pneumonia plus bac-
teremia, or death attributable to P. aeruginosa infection,
are associated with the expression of T3SS proteins by
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patient clinical isolates [4-6]. These observations are in
agreement with multiple in vitro and animal studies
which have demonstrated that the T3SS is required for
both cytotoxicity toward tissue culture cells and virulence
in animals following P. aeruginosa infection [7,8].
The T3SS of P. aeruginosa consists of a multiprotein chan-
nel that spans the inner membrane, periplasm and outer
membrane of the bacterium (reviewed in [9,10]). This
channel mediates the secretion of four exotoxins, namely
ExoS, ExoT, ExoU and ExoY [2,8,11,12]. Three additional
proteins, called PopB, PopD and PcrV, are also secreted by
the T3SS. In the presence of mammalian cells, PopB,
PopD and PcrV enable formation of a pore structure, or
"translocon", in the eukaryotic cell membrane that allows
passage of the exotoxins into the cytoplasm of mamma-
lian host cells [13,14]. Although the in vivo signals which
trigger T3S are poorly understood, production and secre-
tion of the effectors can be induced in vitro by growing the
bacteria in media containing a calcium chelator such as
nitrilotriacetic acid (NTA) [9].
The individual P. aeruginosa exotoxins have been charac-
terized in significant detail. ExoU is a phospholipase
which causes cell necrosis; it requires an as-yet-unidenti-
fied eukaryotic co-factor for activity [15-18]. Expression of
ExoU by P. aeruginosa strains strongly predicts virulence in
murine models of acute pneumonia [7]. There is a trend
toward more severe disease in patients with ventilator-
associated pneumonia infected with ExoU-secreting iso-
lates in the study of Hauser et al. which is not statistically
significant (p = 0.22), but the relationship is stronger than
that measured for any other effector [5]. The effectors
ExoT and ExoS are highly related bifunctional proteins
with both GTPase activating protein (GAP) activity
toward Rho-family proteins, and ADP-ribosyltransferase
activity toward non-overlapping sets of substrates [19-23].
Both proteins inhibit actin cytoskeleton rearrangements,
resulting in tissue culture cell detachment and inhibition
of phagocytosis. Of the two, ExoS contributes more to P.
aeruginosa  virulence in animal models, in a manner
dependent upon its ADP-ribosyltransferase activity
[24,25]. The last known effector, ExoY, is a calmodulin-
dependent adenylate cyclase [12]. No clear role for ExoY
has been established in P. aeruginosa pathogenesis
[25,26]. Clinical P. aeruginosa isolates express various sub-
sets of these four effectors, which has led many investiga-
tors to hypothesize that the varied manifestations of P.
aeruginosa infection may in part reflect the exotoxin com-
plement produced by the infecting organism.
The association of T3S and disease severity suggests that
knowing the T3SS phenotype of a clinical isolate may aid
physicians involved in treating patients from whom P.
aeruginosa is cultured. The isolation of an ExoU producing
strain may prompt a more aggressive treatment algorithm
Table 1: Reference bacterial strains used in this study
Strain Relevant characteristic(s)a Reference(s) or source
PA103 Virulent lung isolate of P. aeruginosa; known type III secreted 
effector proteins are ExoT and ExoU
[45, 46]
PAO1 Reference P. aeruginosa strain; known type III secreted effector 
proteins are ExoS, ExoT and ExoY
[47, 48]
mutN PA103pscJ::Tn5GmR; defective in Type III secretion [39]
PA103∆U PA103 with an in-frame deletion of amino acids (aa) 330–571 of 
ExoU
[35]
PA103∆TP A 1 0 3  w i t h  a  xylE aacC1 cassette replacing aa 36–348 of exoT; 
GmR
[35]
PA103∆U∆TP A 1 0 3 ∆U with a xylE aacC1 cassette replacing aa 36–348 of 
exoT; GmR
[35]
PA103∆pcrV PA103 with an in-frame deletion of aa 10–277 of PcrV (L. Li, L. Mijares, and B. I. Kazmierczak, submitted for 
publication)
PA103∆popD PA103 with an in-frame deletion of aa 7–274 of PopD (L. Li, L. Mijares, and B. I. Kazmierczak, submitted for 
publication)
PA103∆popB PA103 with an in-frame deletion of aa 11–371 of PopB (L. Li, L. Mijares, and B. I. Kazmierczak, submitted for 
publication)
a GmR, gentamicin-resistant.Annals of Clinical Microbiology and Antimicrobials 2005, 4:22 http://www.ann-clinmicrob.com/content/4/1/22
Page 3 of 14
(page number not for citation purposes)
or longer duration of therapy, while the isolation of a
T3SS-negative isolate may support less aggressive manage-
ment in select patient populations. Several investigators
are developing treatment strategies that specifically target
the T3SS, such as antibodies directed against PcrV or small
molecule inhibitors of the T3SS itself [13,27-31]. To use
such strategies most effectively, a treating physician would
require timely information about the capacity of a clinical
isolate to express the T3SS and the specific exotoxins that
it secretes. Unfortunately, the immunoblotting tech-
niques used by research laboratories to characterize T3SS
profiles of P. aeruginosa isolates are ill-suited to either
large-scale clinical trials or to rapid clinical sample testing.
We have therefore developed a rapid quantitative test
which detects four proteins secreted by the T3SS, namely
PcrV, PopD, and the two exotoxins ExoU and ExoT.
Unlike immunoblotting, this assay can be performed on
hundreds of samples per day in a format accessible to
most clinical microbiology laboratories. We show that our
assay results are concordant with those obtained by
immunoblotting and accurately predict virulence of clini-
cal isolates toward epithelial cells. We suggest that this
assay may be ideally suited for large-scale clinical studies
designed to examine prospectively the impact of T3SS-
related virulence factors on P. aeruginosa disease in human
patients.
Methods
Bacterial strains and culture media
Reference bacterial strains are listed in Table 1. Bacteria
were maintained as frozen stocks in 15% glycerol at -80°C
and freshly streaked to Luria Broth (LB) agar plates prior
to each experiment. For analysis of Type III secretion, a
single colony was used to inoculate 1–3 ml of MinS,
which contains the divalent cation chelator NTA, [32] and
grown with vigorous aeration at 37°C.
Pseudomonas aeruginosa clinical isolates
Seventy-four clinical isolates of Pseudomonas aeruginosa
were obtained from the Laboratory of Clinical Microbiol-
ogy at Yale-New Haven Hospital during a 6 month period.
Clinical isolates were identified as P. aeruginosa if they
grew as non-lactose fermenting colonies on MacConkey
agar, were oxidase-positive, could utilize acetamide as a
sole carbon source, and gave a characteristic zone of inhi-
bition to colistin on Kirby-Bauer plates. The presence of
characteristic pigment and "grape-like" odor were also
noted. Any isolates which could not be conclusively iden-
tified based on the above criteria were also tested for the
ability to grow in broth at 42°C. The date of isolation and
the type of clinical specimen from which the strain was
obtained were recorded. Each strain was given a unique
identifying number between CI001 and CI079. No
patient identifiers were recorded, and no clinical informa-
tion was available to differentiate isolates from acutely
infected patients versus isolates from Cystic Fibrosis
patients. The most common specimen types were blood
(n = 19), urine (n = 19), sputum (n = 18); the remainder
of the isolates derived from deep wound, bone, sinus,
bile, eye or stool cultures. Each strain was cultured in 3 ml
LB medium and stored as a frozen stock in 15% glycerol.
Purification of ExoU and PcrV
Native ExoU and PcrV were purified from Pseudomonas
culture supernatants. Pseudomonas aeruginosa strain PA103
was grown thirteen hours in MinS. Culture supernatant
was pooled and concentrated by ultrafiltration on a Pelli-
con XL cassette with a Biomax-10 membrane (Millipore,
Billerica MA). The buffer was changed to 25 mM TrisHCl
pH 8 by dilution and concentration on the same device.
The material was then applied to a MonoQ HR5/5 ion-
exchange column (Amersham Pharmacia) and eluted
with a 0–0.6 M NaCl gradient in 25 mM TrisHCl pH8.
This procedure yielded ExoU and PcrV with purities esti-
mated at ≥90%. ExoU, which is the most abundant pro-
tein in culture supernatants, was identified by its apparent
molecular weight. As PopD and PcrV have similar appar-
ent molecular weights, the identity of PcrV was deter-
mined by tryptic digestion of the purified protein
extracted from a gel slice following SDS-PAGE. The tryptic
fragments were analyzed by MALDI-MS (Keck Biotechnol-
ogy Center, Yale University). An automated search of sev-
eral databases unambiguously confirmed that the purified
protein was PcrV.
Hybridomas producing monoclonal antibodies against 
ExoU and PcrV
All animal work was performed according to protocols
approved by the Yale University Institutional Animal Care
and Use Committee (IACUC). Six-week old female Balb/
c mice (NCI) were immunized with 20 µg of ExoU or 5 µg
of PcrV in complete Freund's adjuvant. The mice were
boosted twice at 3 week intervals with the same amount
of antigen in incomplete Freund's adjuvant. Two weeks
after the second boost, spleen cells were harvested and
fused with Ag8 myeloma cells (ATCC). The resulting
hybridoma cells were selected in hypoxanthine, aminop-
terin, and thymidine (HAT) culture medium using stand-
ard procedures. Hybridoma cells underwent three rounds
of cloning by limiting dilution and were then expanded
and frozen.
After each round of cloning, positive cultures were identi-
fied by an enzyme-linked immunoassay using purified
ExoU or PcrV as antigen. Bound antibodies were detected
with an alkaline phosphatase-conjugated goat anti-mouse
IgG antibody (Sigma, St Louis MO). The chromogenic
substrate paranitrophenyl phosphate (PNPP) (Sigma)
was used in all experiments.Annals of Clinical Microbiology and Antimicrobials 2005, 4:22 http://www.ann-clinmicrob.com/content/4/1/22
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Hybridomas producing monoclonal antibodies against 
ExoT and PopD
We were unable to purify soluble ExoT and PopD from
culture supernatants. We therefore used insoluble viru-
lence factor aggregates, which form after prolonged cul-
ture in calcium-free medium, as a source of antigen [8].
These aggregates were collected from 18 hour MinS cul-
tures of strain PA103, washed several times with phos-
phate buffered saline (PBS) and solubilized with 4% SDS.
Six-week old female Balb/c mice were immunized with
100 µg of solubilized aggregates emulsified with complete
Freund's adjuvant. Mice were boosted twice at three week
intervals with the same amount of antigen in incomplete
Freund's adjuvant. Hybridomas were purified as described
above. Antibody-producing hybridomas were identified
by ELISA, using supernatants from overnight cultures of P.
aeruginosa strain PAO1 as antigen. (PAO1 does not pro-
duce ExoU, which avoided the isolation of additional
anti-ExoU hybridomas.) Bound antibodies were detected
as described above. The specificity of the antibodies pro-
duced was determined in two steps. The molecular weight
of the antigen recognized was determined by immunob-
lotting against a PAO1 culture supernatant (as described
below). The identity of the antigen recognized was then
confirmed by preparing culture supernatants from mutant
laboratory strains lacking individual T3SS components
(Table 1). Antibody binding to these culture supernatants
was determined in immunoblotting and ELISA experi-
ments.
Purification and characterization of monoclonal 
antibodies
Hybridomas were grown in Hybridoma-SFM serum-free
medium (Invitrogen, Carlsbad CA) after a short adapta-
tion period. Each monoclonal antibody was purified from
hybridoma culture supernatant by affinity chromatogra-
phy on protein G-agarose (Amersham, Piscataway NJ).
Isotypes were identified with the ImmunoPure Mono-
clonal Antibody Isotyping Kit (Pierce, Rockford IL).
We produced several monoclonal antibodies specific for
each of the four T3SS proteins under investigation. To
determine whether more than one epitope was recognized
in each protein, we performed antibody competition
assays in an ELISA format. Each purified immunoglobulin
was covalently labeled with horseradish peroxidase
(HRP) using EZLink Peroxidase (Pierce) according to the
manufacturer's instructions. 96-well plates were coated
with a PA103 culture supernatant diluted in carbonate
buffer. Each antibody (0.5 – 8 µg/ml) was allowed to react
with the bacterial proteins in the presence of a 50-fold
excess of unlabeled competing antibody. HRP conjugated
antibodies were detected with SureBlue™ chromogenic
substrate (KPL, Gaithersburg MD). The unlabeled anti-
body was considered to bind to the same epitope as the
labeled antibody if it reduced binding of the labeled anti-
body by at least 75%. We found that the reactivity of IgG1
antibodies was greatly diminished by the HRP conjuga-
tion. As an alternative, we therefore non-covalently
labeled each IgG1 antibody with an alkaline phosphatase-
conjugated anti-IgG1 Fab fragment (Zenon™ technology,
Invitrogen). The competition assay was performed as
before, except that alkaline phosphatase labeled antibod-
ies were detected with PNPP. Identical conclusions were
reached with the two labeling methods.
Polyclonal antiserum against secreted T3SS components
Insoluble aggregates containing T3SS components were
prepared from PA103 supernatants as described above
and dissolved in 4% SDS. Two New Zealand white rabbits
(Cocalico Biologicals, Inc.) were each immunized with
100 µg of solubilized antigen emulsified in complete Fre-
und's adjuvant. Three weeks later the rabbits received a
booster injection of 100 µg of antigen in incomplete Fre-
und's adjuvant. Serum samples were collected at two-
week intervals for four months. The endpoint titer of this
antiserum was >1:32,000 by ELISA with PA103 culture
supernatant used as antigen.
Detection of Type III secretion system components by 
immunoblotting
T3SS components were detected by immunoblotting
using our rabbit polyclonal antiserum or monoclonal
antibodies. Proteins in 1 mL samples of Pseudomonas cul-
ture supernatant were concentrated by precipitation with
10%(v/v) trichloroacetic acid (TCA). The pellets were
washed once with acetone and redissolved in SDS gel elec-
trophoresis sample buffer. The proteins were separated by
SDS-PAGE and transferred to PVDF (Immobilon-P, Milli-
pore). Blots were blocked in Tris-buffered saline plus
0.1% Tween-20 (TBST) containing 5%(w/v) dry milk for
30 min prior to applying anti-T3SS rabbit antiserum at a
dilution of 1:20,000 in TBST plus milk. HRP-conjugated
goat anti-rabbit IgG (Biorad) diluted 1:2,000 was used as
secondary antibody. Proteins were visualized by incubat-
ing membranes in 225 µM coumaric acid (Sigma), 1.25
mM 3-aminophthalhydrazide (Fluka) and 0.009% hydro-
gen peroxide (Fisher Scientific) in 100 mM Tris-HCl pH
8.5 for 1 min. Chemiluminescence was detected with an
Image Station 2000R using 1D Image Analysis software v.
3.6 (Kodak). The exotoxins ExoU, ExoT and ExoS as well
as the translocon components PopB and PopD could be
detected simultaneously. The identity of each protein
band was confirmed by comparing the immunoblot pat-
tern obtained from culture supernatants of wild-type
strains versus isogenic defined mutant strains (Table 1).
PcrV was not detected by this polyclonal serum, but could
be detected by a similar procedure with the monoclonal
antibody RC (this study) used at a concentration of 0.1Annals of Clinical Microbiology and Antimicrobials 2005, 4:22 http://www.ann-clinmicrob.com/content/4/1/22
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µg/ml, followed by incubation with HRP-conjugated goat
anti-mouse IgG (Biorad).
Quantitative detection of components of the Type III 
secretion system by ELISA
Each Pseudomonas clinical isolate was tested for produc-
tion of T3SS components in 2–6 independent assays using
an ELISA optimized by multiple checkerboard titrations.
Each Pseudomonas strain was grown with vigorous agita-
tion for 12–16 hours in 1–3 ml MinS at 37°C. Culture
supernatants were cleared by centrifugation at 7,000 × g
for ten minutes, then diluted 20-fold with 50 mM carbon-
ate buffer pH 9.6 and used to coat 96-well plates for two
hours at 37°C. Monoclonal antibodies were diluted to 1
µg/ml in PBS containing 0.05% Tween-20 (PBS-T) and
0.5% dry milk, applied to the plates, and allowed to react
for one hour at room temperature. A secondary antibody
(alkaline phosphatase-conjugated goat anti-mouse IgG,
Sigma) was applied at a dilution of 1:3,000 in PBS-T and
allowed to react for one hour at room temperature. After
both incubations, unbound antibody was removed by
washing three times with PBS-T. Bound antibody was
detected with PNPP.
Negative control wells were coated with a culture superna-
tant from the Pseudomonas mutN strain, which does not
secrete any component of the T3SS. For each monoclonal
antibody, the optical density observed in the negative
control wells was subtracted from all experimental values.
On every 96-well plate, eight positive control wells were
coated with a frozen reference aliquot of PA103 culture
supernatant. The signals observed with experimental clin-
ical isolates were expressed as a percentage of the signal
obtained with the PA103 culture supernatant. Two mon-
oclonal antibodies were used to detect each T3SS compo-
nent, and the signals obtained with each were averaged. A
strain was considered positive for a T3SS component if the
averaged antibody signal was at least 10% that seen with
the PA103 strain.
Detection of genes encoding ExoS, ExoT, ExoU, PcrV, and 
PopD by PCR
The presence of genes encoding T3SS components was
determined by PCR amplification of bacterial DNA using
pairs of gene-specific primers. Single colonies were sus-
pended in 10 µl of water and boiled for five minutes. One
microliter of this preparation was used as the source of
DNA for PCR reactions. Table 2 lists the primers used as
well as the cycling conditions.
Cytotoxicity assay
The ability of Pseudomonas strains to induce necrosis of
HeLa cells (ATCC) was determined by measuring lactate
dehydrogenase (LDH) release, as described before [33].
Each clinical isolate was assayed in triplicate in 2–3 inde-
pendent assays. A strain was scored as positive in this
assay if the bacteria caused at least 25% as much necrosis
as the laboratory strain PA103 at 2 h post-infection.
Cell rounding assay
Pseudomonas bacteria were grown as for cytotoxicity assays
prior to infecting HeLa cells at an MOI of ca. 10. Each
strain was assayed in triplicate in 2–3 independent assays,
with PAO1 and mutN strains serving as positive and neg-
ative controls for each experiment. Cells were observed by
phase-contrast microscopy after three hours of bacteria-
host cell contact. A strain was considered to cause cell-
rounding if fewer than 50% of HeLa cells remained
Table 2: PCR parameters for the detection of genes encoding TTSS components
Gene Forward & reverse primer sequences 
(all primers listed 5' to 3')
PCR conditions
exoS S1: ATGGCGTGTTCCGAGTCA Annealing temperature step-down 1°C/cycle (8 cycles) from 62°C to 55°C, 
followed by 25 cycles at 54°C. All extensions carried out at 72°C for 90 sec.
S2: AGGTGTCGGTTCGTGACGTCT
exoT T1: GAGAGGCTGGCGAAGGATCAC
T2: CCAGGTCCAGAGCATCGAGCA
exoU U1: GGCACATATCTCCGGTTCCTTC
U2: TCAACTCAGCTGCCAACCATGC
pcrV V1: ATGGAAGTCAGAAACCTTAATGCCG Annealing temperature step-down 1°C/cycle (8 cycles) from 58°C to 51°C, 
followed by 25 cycles at 50°C. All extensions carried out at 72°C for 75 sec.
V2: CTAGATCGCGCTGAGAATGTC
popD D1: ATGATCGACACGCAATATTCCC
D2: TCAGACCACTCCGGCCGCCGCAAnnals of Clinical Microbiology and Antimicrobials 2005, 4:22 http://www.ann-clinmicrob.com/content/4/1/22
Page 6 of 14
(page number not for citation purposes)
attached and maintained their characteristic elongated
cell shape at 3 h post-infection.
Results
Monoclonal antibodies against ExoU, ExoT, PcrV, and 
PopD
We generated twelve novel hybridoma cell lines produc-
ing monoclonal antibodies specific for T3SS components
(Table 3). The specificity of each antibody in our ELISA
assay was verified by testing its reactivity against culture
supernatants of isogenic strains lacking specific T3SS com-
ponents. These experiments showed that each mono-
clonal antibody is specific for a single T3SS component
(Figure 1 and data not shown). The specificity of each
antibody was further confirmed by immunoblotting
experiments (data not shown). Of note, none of the anti-
ExoT monoclonal antibodies recognized the closely
related protein ExoS in immunoblots. Each monoclonal
antibody was purified and its isotype determined. As
Table 3 shows, most antibodies consisted of γ1 heavy
chains and κ light chains.
ExoU, ExoT, PcrV, and PopD were each recognized by sev-
eral monoclonal antibodies. In order to determine
whether the antibodies recognized the same epitopes, we
performed antibody competition experiments. Represent-
ative results are shown in Figure 2. The antibodies recog-
nize four distinct epitopes on ExoU; two of these anti-
ExoU antibodies (UA and UC) exhibit cooperative bind-
ing. RC and RD antibodies recognize distinct epitopes on
PcrV, while DA and DB recognize overlapping or identical
epitopes on PopD. One epitope of ExoT is recognized by
TA while another is recognized by both TB and TC.
For all further experiments, we selected a panel of mono-
clonal antibodies (TA, TB, UA, UB, RC, RD, DA, and DB)
based upon their specificity and sensitivity.
Quantitative detection of T3SS components by ELISA
ELISA assay parameters were optimized in a series of pre-
liminary experiments. Each antibody was evaluated at sev-
eral concentrations ranging from 0.05 to 9 µg/ml, using
PA103 culture supernatant as antigen. Panel A of Figure 3
shows the results of a titration experiment for the three
monoclonal antibodies specific for PcrV, namely RA, RB
and RC. Increasing the antibody concentration led to
higher optical densities. For these and all other antibod-
ies, there was little benefit to be gained by using concen-
trations higher than 1 µg/ml (data not shown). We
therefore performed all subsequent experiments at an
antibody concentration of 1 µg/ml.
To verify that the result of the ELISA is proportional to the
amount of antigen in the sample analyzed, we mixed
PA103 culture supernatant with a culture supernatant
derived from an isogenic defined mutant lacking a single
T3SS component. These mixtures thus contain a variable
amount of one T3SS component and relatively constant
concentrations of other proteins. Figure 3, panel B shows
the results of such an experiment with the antibodies UA
and UB, which are specific for ExoU. The data shown are
the average of the values obtained for the two antibodies.
The samples mixed were culture supernatants from PA103
(wild-type) and PA103∆U, an isogenic mutant lacking the
exoU  gene. When the mixed culture supernatants were
diluted 40-fold with carbonate buffer prior to coating the
plates, the ELISA signal was proportional to the percent-
Table 3: Isotypes of monoclonal antibodies recognizing TTSS components ExoT, ExoU, PcrV, and PopD
TTSS Component Recognized Monoclonal Antibody Isotype – Heavy Chain Isotype – Light Chain
ExoT TA IgG1 Kappa
TB IgG1 Kappa
TC IgG1 Kappa
ExoU UA IgG1 Lambda
UB IgG1 Kappa
UC IgG1 Kappa
UD IgG2a Kappa
PcrV RA IgG1 Kappa
RC IgG1 Kappa
RD IgG1 Kappa
PopD DA IgG2b Kappa
DB IgG2a KappaAnnals of Clinical Microbiology and Antimicrobials 2005, 4:22 http://www.ann-clinmicrob.com/content/4/1/22
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age of ExoU-containing PA103 supernatant in the antigen
mixture. Thus under these conditions, ELISA results are
proportional to the amount of ExoU in the sample tested.
Coating plates with culture supernatant mixtures diluted
10- or 20-fold increased the signal observed at low ExoU
concentrations, but resulted in a flattening of the dose-
response curve at higher ExoU concentrations (Fig. 3B).
Similar results were obtained with ExoT, PopD and PcrV
antigen-antibody combinations (data not shown). We
used a 20-fold dilution of culture supernatant for our
experiments, unless otherwise indicated, as this provides
good sensitivity and correlation with the amount of anti-
gen plated.
Production and secretion of T3SS components by 
Pseudomonas clinical isolates
We studied the secretion of T3SS components by 74 P. aer-
uginosa isolates obtained from the Laboratory of Clinical
Microbiology at Yale-New Haven Hospital using eight
monoclonal antibodies in our ELISA format as described
above. In each assay, frozen aliquots of reference PA103
and mutN culture supernatants were used as positive and
negative controls, respectively. We considered a strain to
be positive if it secreted at least 10% of the amount of
T3SS component present in the PA103 supernatant. We
arrived at this cut-off by determining the standard devia-
tion of our negative control, the mutN supernatant, in
over 20 independent assays performed by two different
operators (K. K. and M. L.). Values three standard devia-
tions above the negative control were considered positive;
this corresponded to 10% of the positive control when
averaged for all 8 antibodies (range, 6–17%).
Using this criterion, 15 of 74 isolates (20%) were positive
for ExoU, ExoT, PcrV, and PopD (Table 4). 47 isolates
(64%) were positive for ExoT, PcrV, and PopD but nega-
Specificity of monoclonal antibodies against TTSS components Figure 1
Specificity of monoclonal antibodies against TTSS components. Monoclonal antibodies generated against ExoU, PcrV, 
PopD and ExoT were tested in the ELISA assay format against culture supernatants prepared from PAO1, PA103 and defined 
mutants isogenic with the laboratory strain PA103. Note that PAO1 does not produce or secrete ExoU.
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tive for ExoU. Finally, 12 isolates (16%) were negative for
all four T3SS components by ELISA. The proportion of
ExoU positive strains was particularly high among isolates
derived from blood (6 out of 19, or 32%), as has been
described before [4]. These results are presented graphi-
cally in Figure 4, in which each data point represents the
amount of ExoU, ExoT, PcrV or PopD secreted by an indi-
vidual isolate as measured by ELISA.
We also assayed strains for secretion of T3SS proteins by
immunoblotting using our polyclonal rabbit antiserum,
which recognizes ExoU, ExoT, ExoS, PopB and PopD. This
antiserum does not recognize the fourth known P. aerugi-
nosa effector, ExoY, whose secretion does not appear to be
associated with increased virulence in vitro or in vivo
[25,26,34]. We found that the majority of clinical isolates
secreted the effectors ExoU plus ExoT (n = 15) or ExoS
plus ExoT (n = 45). Only one isolate secreted all three
effector proteins (CI052), and only one other secreted
ExoT alone. These findings are in agreement with other
studies, which report that ExoU and ExoS are very rarely
secreted by the same isolate [6,24,26] (data not shown).
We were particularly interested in whether any of the 12
strains which scored negative for Type III protein secretion
by ELISA would show detectable secretion of T3SS pro-
teins by immunoblotting, especially as the maximum
amount of supernatant assayed by Western (675 µl/lane,
concentrated by TCA precipitation) was substantially
greater than that assayed in our ELISA (5 µl/well). In only
one case (CI051) were we able to detect secretion by
immunoblotting that was undetectable by ELISA (data
not shown). In all other cases, ELISA and immunoblotting
assays yielded concordant results.
Many  P. aeruginosa strains possess genes encoding the
T3SS effectors, translocators and apparatus proteins, but
nonetheless fail to produce or secrete these proteins
[4,5,12,26]. We examined which clinical strains possessed
the exoU, exoT, pcrV, and popD genes by PCR. We found
that 12 strains did not secrete T3SS components as meas-
ured by ELISA even though they possessed the corre-
sponding structural genes. We confirmed that our
negative ELISA results were not due to extracellular pro-
tease production by these isolates by comparing assay
results for a subset of these isolates (and the laboratory
strain PA01) cultured in MinS or in MinS plus protease
inhibitors (Complete™, EDTA-free, Boehringer-Man-
nheim). The presence of protease inhibitors completely
inhibited the appearance of ExoT degradation products
when culture supernatants were assayed by Western blot-
ting with monoclonals TA and TB; however, no difference
in ELISA results was noted for any isolate (data not
shown). Thus, our failure to detect T3SS proteins was not
due to their degradation by secreted proteases. We con-
clude, therefore, that T3SS secretion profiles are not accu-
rately predicted by the genotype of a given strain in 16%
of our clinical isolates.
Strains that do not secrete T3SS effectors may fail to syn-
thesize these proteins or may fail to export them into the
culture medium. We therefore further tested all strains
that scored negative for T3S by ELISA and by immunob-
lotting, to see whether effectors are produced but retained
within the bacteria. Bacteria were grown in MinS as per
routine for ELISA assay, collected by centrifugation, and
lysed with 4% SDS. The presence of T3SS components was
assessed by immunoblotting as described in the Methods.
We found that only one isolate (CI042) produced T3SS
proteins but failed to secrete them into the culture
medium (data not shown). Thus the ELISA and immuno-
blotting results were concordant for all clinical isolates
with the exception of CI051, and only one isolate (CI042)
produced but did not secrete TTSS proteins when grown
in calcium-free medium.
Secretion of TTSS proteins by P. aeruginosa cultured in 
calcium-free medium predicts TTSS-dependent virulence 
in cell-based assays
T3S is normally activated upon contact with host cells.
However, T3S phenotypes are usually determined by cul-
turing bacteria in media containing calcium chelators
Competition between monoclonal antibodies against TTSS Figure 2
Competition between monoclonal antibodies against 
TTSS. Binding of antibodies to antigens derived from PA103 
culture supernatants was measured in an ELISA assay as 
described in Material and Methods. Numbers show the per-
centage of labeled antibody binding in the presence of a 50-
fold excess of competing antibody. Inhibition of 75% or more 
(numbers in bold italics) indicates that the two antibodies 
compete for the same epitope. The binding of the RA anti-
body was too weak to yield reliable quantitative results.
Labeled antibody
Competing
Antibody TA TB TC UA UB UC UD RA RC RD DA DB
TA 1 93 88
TB 54 74 96 97
TC 96 94
UA 100 95 89 14 76 255 71 84 66
UB 105 10 123 61
UC 234 85 24 80
UD 96 78 74 3
RA 77 86
RC 99 84 82 105 103 85 1 86
RD 96 52 0
DA 00
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[4,5,12,26]. T3SS profiles of laboratory isolates deter-
mined in vitro usually predict ExoU-, ExoS- or ExoT-
dependent effects on infected host cells. We examined
whether this correlation held true for our clinical isolates.
We thus assayed whether our clinical isolates cause rapid
cytotoxicity, a phenomenon attributable to ExoU [8,11],
Optimization of ELISA assay parameters Figure 3
Optimization of ELISA assay parameters. A. Increasing concentrations of monoclonal antibodies RA, RC and RD were 
used in the ELISA assay with a constant amount of PA103 culture supernatant serving as bound antigen. B. PA103 and 
PA103∆U culture supernatants were mixed in the proportions indicated to vary the amount of ExoU present in each sample 
while holding other secreted antigens constant. The mixed supernatants were diluted with carbonate buffer as indicated, then 
assayed by ELISA using antibodies UA and UB. Values represent the average of the signal obtained with the two antibodies.
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and/or cell rounding and detachment, phenotypes associ-
ated with ExoT and ExoS translocation [35-37]. We
included clinical isolates that were T3SS-negative by our
ELISA to test whether they would elicit T3SS-dependent
phenotypes upon contact with epithelial cells.
We first determined which strains caused rapid cytotoxic-
ity by measuring LDH release from infected HeLa cells 2 h
post-infection. We found that ExoU secretion in vitro as
assayed by ELISA was strongly associated with the ability
to cause tissue culture cell necrosis (see Table 4). 14 out of
15 isolates that secreted ExoU in vitro caused HeLa cell
necrosis at 2 h post-infection, as measured by LDH release
≥25% of that seen with PA103 infected cells. One isolate,
CI022, did not cause cell necrosis despite secreting ExoU
in vitro. Interestingly, this isolate also did not cause cell
rounding (see below), indicating that it fails to establish a
productive interaction with epithelial cells. This strain is
deficient for Type IV pilus-dependent motility, as evi-
denced by its lack of twitching motility in a subsurface
agar stab assay [38] (data not shown). It is well-estab-
lished that twitching motility deficient strains are mark-
edly attenuated for T3SS-dependent virulence as
measured by cell-based assays such as LDH release and
cell rounding [39]. In agreement with ELISA results, no
cell necrosis was caused by isolates CI034 and CI070,
which possess the exoU gene but do not secrete ExoU in
vitro. We attempted to correlate the amount of ExoU
secreted by clinical isolates during growth in MinS with
the amount of cytotoxicity these strains caused, as meas-
ured by LDH release at 2 hpi; however, no such corre-
spondence was observed (data not shown).
We also performed cytotoxicity testing for 31 of the 45 iso-
lates which were ExoU-/ExoS+/ExoT+ and did not possess
the exoU gene. None of the 31 isolates scored positive for
LDH release (range, 0.2 to 3.2% of PA103 infected control
at 2 hpi). This group included isolates that gave detectable
ELISA values (5–8%) that were nonetheless below our
10% cut-off. Thus, the association between ExoU secre-
tion as scored by ELISA and rapid cytotoxicity caused by
our clinical isolates was robust.
We then performed cell rounding assays with each of the
72 clinical isolates that are positive by PCR for the mini-
mum T3SS gene set of pcrV, popD and exoT (Table 4). As
cell rounding is considered a measure of ExoT and/or
ExoS translocation into host cells and subsequent disrup-
tion of the actin cytoskeleton [20,40], this assay serves as
a sensitive test of whether the T3SS phenotype predicted
by our in vitro ELISA test correlates with the capacity of
each isolate to produce, secrete and translocate ExoT and/
or ExoS upon contact with tissue culture cells. Bacterial
strains lacking a functional T3SS (mutN) or lacking the
effectors ExoU, ExoT and ExoS (PA103∆U∆T) served as
negative controls for this assay. All ExoU-secreting strains,
with the exception of CI022 (see above), caused visible
cell rounding in addition to measurable LDH release. All
of these strains also secrete ExoT. Of the 47 ExoU-nega-
tive, ExoT-positive isolates assayed for cell rounding, 45 of
47 caused rounding equivalent to PAO1 (Table 4). The
two isolates which failed to cause cell rounding, CI024
and CI047, do not exhibit twitching motility in a subsur-
face agar stab assay (data not shown).
We also assayed all 10 of the strains that were negative for
protein secretion by ELISA, but possessed genes for exoT,
popD and pcrV. Eight of these 10 isolates caused no cell
rounding, as expected from the ELISA results. One of the
two isolates that caused cell rounding was CI051, already
mentioned above. ELISA and immunoblot results demon-
strate that T3SS secretion by CI051 is approximately 5%
that of the PA103 strain, which is below the cutoff for a
positive ELISA result. The second isolate was CI042,
which showed production, but not secretion, of T3SS
components when grown in MinS. This suggests that
Table 4: Genotypes and phenotypes determined for 74 clinical 
isolates.
Genotypea Phenotypeb Cell Roundingc Cytotoxicityc
exoU+ 17 ExoU+ 15 14/15 14/15
exoT+ ExoT+
popD+ PopD+
pcrV+ PcrV+
ExoU- 2 0/2 0/2
ExoT-
PopD-
PcrV-
exoU- 55 ExoU- 46 44/46 0/31
exoT+ ExoT+
popD+ PopD+
pcrV+ PcrV+
ExoU- 7 2/7 N.D.
ExoT-
PopD-
PcrV-
otherd 2 1/2 N.D.
exoU- 2 ExoU- 2 0/2 N.D.
exoT- ExoT-
popD- PopD-
pcrV- PcrV-
a Presence or absence of genes determined by PCR.
b Determined by ELISA.
c Results expressed as number of positive isolates/number of isolates 
tested.
d One isolate each with phenotypes ExoU-/ExoT-/PopD+/PcrV- and 
ExoU-/ExoT+/PopD+/PcrV- N.D., not determined.Annals of Clinical Microbiology and Antimicrobials 2005, 4:22 http://www.ann-clinmicrob.com/content/4/1/22
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CI042 might secrete T3SS proteins only in response to
host cell contact, and not in response to MinS.
Discussion
ELISA-based detection of TTSS components of 
Pseudomonas aeruginosa
In this work we describe a rapid ELISA-based assay that
detects secretion of four T3SS effector and translocator
proteins. This assay shows excellent concordance with
immunoblotting: only one sample classified as T3SS-neg-
ative by ELISA (CI051) showed T3SS protein secretion by
immunoblotting, under conditions which allowed us to
assay ca. 135-fold more antigen. The assay is easily
adapted to clinical and research laboratory settings. The
ELISA can analyze many samples simultaneously, at less
cost and in less time than immunoblotting. In addition,
the ELISA assay yields quantitative results, while immuno-
blotting typically gives qualitative results unless special
procedures are followed. Thus, this assay is well-suited for
clinical and research laboratory analysis of Type III secre-
tion phenotypes of clinical and environmental P. aerugi-
nosa isolates.
Clinical isolates exhibit various deficiencies in their Type 
III secretion system
Several studies have found that P. aeruginosa clinical iso-
lates show significant variability in secreting T3SS effec-
tors [4,5,12,26]. Our study is no exception: a number of
distinct secretion patterns appeared amongst the 74 iso-
lates we examined. Sixty-three strains secreted a core
group of effectors and translocators, namely ExoT, PcrV,
PopD and PopB (the last assayed by immunoblotting).
Fifteen of these strains also secreted ExoU, 46 strains
secreted ExoS, one strain secreted both ExoU and ExoS,
and one strain secreted neither. The presence of genes
encoding these proteins in a P. aeruginosa isolate is not
predictive of T3SS production or secretion. Seventy-two of
74 isolates possessed genes encoding PcrV, PopB, PopD
and ExoT, but 11 failed to secrete any of these proteins as
measured by ELISA and immunoblotting. Thus, methods
based solely on detection of gene sequences in clinical iso-
lates are unlikely to predict T3SS-dependent phenotypes.
The absence of secretion was not generally due to defects
in the secretion apparatus: only one clinical isolate
(CI042) appropriately produced T3SS proteins but failed
to secrete them into culture medium. The remaining 9
secretion negative isolates failed to produce T3SS proteins
in response to growth in MinS, suggesting that the regula-
tory networks that induce transcription of T3SS genes in
response to calcium chelation no longer function in these
strains.
T3S profiles in vitro predict T3SS-dependent virulence 
toward epithelial cells
The T3SS is triggered by contact between bacteria and host
cells during infection, resulting in the translocation of
bacterial effector proteins into host cells. We characterized
all 74 clinical isolates in tissue culture cell-based assays
which measure rapid cell necrosis or cell rounding and
detachment, phenotypes which require the translocation
of ExoU or ExoS/ExoT, respectively, into infected host
cells. We then examined whether these phenotypes were
predicted by the in vitro ELISA results we obtained for
each clinical isolate. Sixty-nine of 74 isolates had pheno-
types in tissue culture cell-based assays which were pre-
dicted by their T3SS profiles as measured by ELISA. Only
one strain, CI051, caused cell rounding despite being
scored as negative for T3SS secretion by ELISA. This isolate
secreted very small amounts of T3SS proteins in vitro,
which could only be detected by immunoblotting. There-
fore, our cutoff value for classifying a strain as T3SS-posi-
tive versus negative, i.e. ≥10% of PA103 secretion levels,
appears to be appropriate.
The remaining four strains whose phenotypes were not
correctly predicted by our ELISA assay illustrate additional
factors which influence bacterial virulence. CI022, CI024
and CI047, secreted ExoT, PopD and PcrV (as measured
by ELISA), PopB (as demonstrated by immunoblotting),
and ExoU (in the case of CI022), yet caused neither cell
necrosis (CI022) nor cell rounding when used to infect
HeLa cells. These strains are defective for Type IV twitch-
ing motility, which likely explains their apparent lack of
virulence toward tissue culture cells [39]. Of note, strains
deficient in twitching motility do show virulence in
murine models of acute pneumonia [41](Kazmierczak,
B.I., M. B. Lebron, T. S. Murray, submitted for publica-
tion). It still remains to be determined whether the
absence of twitching motility in T3SS-positive strains
influences the clinical outcomes observed during human
infection.
The last isolate, CI042, caused cell-rounding but did not
secrete T3SS proteins detectable by either ELISA or immu-
noblotting. We demonstrated that CI042 appropriately
synthesized T3SS proteins, which could be detected by
immunoblotting lysates prepared from bacteria cultured
in either calcium-free medium or in the presence of host
cells. Because HeLa cell rounding requires translocation of
bacterial proteins across eukaryotic cell membranes,
CI042 appears to exhibit the previously undescribed phe-
notype of selectively secreting T3SS effectors in response
to host cell contact, but not to calcium chelation.
Although it is possible that CI042 caused HeLa cell round-
ing and detachment through a mechanism independent
of T3SS proteins, such as secretion of extracellular pro-
teases, the following observations support a T3SS-basedAnnals of Clinical Microbiology and Antimicrobials 2005, 4:22 http://www.ann-clinmicrob.com/content/4/1/22
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mechanism. When co-cultured with HeLa cells, CI042
caused cell rounding with the same kinetics as T3SS-posi-
tive strains and produced T3SS effectors that were detected
in bacterial lysates prepared from infected HeLa cell cul-
tures. Cell rounding activity could not be transferred in
cleared and filtered supernatants prepared from CI042-
infected cell cultures, suggesting that cell rounding activity
was cell-associated and not secreted (L. L. and B. K.,
unpublished results). Thus, our results suggest that con-
tact with epithelial cells may trigger secretion of TTSS
effectors through a mechanism that is distinct from that
used to respond to calcium depletion.
Thus in 69 isolates (93%), detection of secreted protein by
ELISA correlated with phenotypic assays examining trans-
location of ExoU (cell necrosis) or of ExoT/ExoS (cell
rounding and detachment). This indicates that secretion
of T3SS effectors in vitro is an excellent predictor of T3SS
effector translocation upon host cell contact for P. aerugi-
nosa strains in general, including clinical isolates. Con-
versely, strains failing to express T3SS proteins under in
vitro conditions are not likely to express them under con-
ditions of host cell contact. The ELISA assay therefore rep-
resents a robust and easy to use tool for future studies
correlating in vitro behavior of P. aeruginosa clinical iso-
lates with in vivo outcomes of infection.
Clinical significance of TTSS-negative clinical isolates
The ability of isogenic series of P. aeruginosa mutants con-
structed in the laboratory to cause disease in murine mod-
els of pneumonia is strongly correlated with their ability
to secrete and translocate the effectors ExoU and, to a
lesser extent, ExoS [24,25,34]. Several studies examining
T3SS profiles of clinical P. aeruginosa isolates isolated
from human patients concluded that T3SS-positive strains
were associated with more severe clinical disease [4-6,26].
In each study, however, T3SS-negative strains were also
isolated from patients who appeared to have severe P. aer-
uginosa infections. No study was designed to control for
host factors that might have influenced severity of infec-
tion, such as underlying host disease or immunocompro-
mise. As each study relied on a single banked clinical
specimen per patient, no study could address the possibil-
ity that more than one P. aeruginosa strain was present
during infection. Jain et al. recently observed that cystic
fibrosis patients can be colonized by multiple strains that
show heterogeneity in their T3SS protein secretion pro-
files, despite being genotypically indistinguishable. It
remains to be determined whether heterogeneous isolates
are also present in acutely infected patients. Virulence fac-
tors other than T3SS proteins may also contribute to clin-
ical virulence of P. aeruginosa strains. The presence or
absence of surface structures, such as Type IV pili and flag-
ella, has been correlated with changes in virulence in ani-
mal models of infection [42-44]. To our knowledge,
however, no study has systematically examined the influ-
ence of such structures on disease severity caused by T3SS+
or T3SS- strains.
In conclusion, the ability to carry out a rapid, simple and
inexpensive assay to determine T3SS profiles enables pro-
spective studies investigating the relationship between P.
aeruginosa expression of these virulence factors and clini-
cal manifestations of infection in a large patient cohort.
Phenotypic assays, including TTSS effector production,
may ultimately have significant prognostic value for clini-
cians caring for patients from whom P. aeruginosa is cul-
tured.
T3SS component production by clinical isolates as measured  by ELISA Figure 4
T3SS component production by clinical isolates as 
measured by ELISA. Each point represents the amount of 
ExoU, ExoT, PcrV or PopD secreted by one of the 74 clinical 
isolates as determined by ELISA. Each value is expressed as 
the percentage of protein present in PA103 supernatants 
(positive control).
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